Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
> 26 27 26 27 O
= 27 28 27 28 O
1,500 29 34 29 34 B-lower_bound
/ 34 35 34 35 I-lower_bound
mcL 35 38 35 38 I-lower_bound

Additionally 0 12 39 51 O
, 12 13 51 52 O
for 14 17 53 56 O
all 18 21 57 60 O
methods 22 29 61 68 O
above 30 35 69 74 O
( 36 37 75 76 O
except 37 43 76 82 O
for 44 47 83 86 O
abstinence 48 58 87 97 O
) 58 59 97 98 O
, 59 60 98 99 O
male 61 65 100 104 B-gender
subjects 66 74 105 113 I-gender
( 75 76 114 115 O
including 76 85 115 124 O
those 86 91 125 130 O
who 92 95 131 134 O
are 96 99 135 138 O
vasectomized 100 112 139 151 B-treatment
) 112 113 151 152 O
whose 114 119 153 158 O
partners 120 128 159 167 O
are 129 132 168 171 O
pregnant 133 141 172 180 B-pregnancy
or 142 144 181 183 O
might 145 150 184 189 B-pregnancy
be 151 153 190 192 I-pregnancy
pregnant 154 162 193 201 I-pregnancy
must 163 167 202 206 O
use 168 171 207 210 B-contraception_consent
condoms 172 179 211 218 I-contraception_consent
for 180 183 219 222 O
the 184 187 223 226 O
duration 188 196 227 235 O
of 197 199 236 238 O
the 200 203 239 242 O
study 204 209 243 248 O
and 210 213 249 252 O
for 214 217 253 256 O
6 218 219 257 258 B-upper_bound
months 220 226 259 265 I-upper_bound
following 227 236 266 275 I-upper_bound
completion 237 247 276 286 O
of 248 250 287 289 O
therapy 251 258 290 297 B-treatment

Adequate 0 8 298 306 O
archival 9 17 307 315 O
tissue 18 24 316 322 O
from 25 29 323 327 O
a 30 31 328 329 O
biopsy 32 38 330 336 B-treatment
performed 39 48 337 346 O
after 49 54 347 352 O
progression 55 66 353 364 O
of 67 69 365 367 O
disease 70 77 368 375 O
on 78 80 376 378 O
previous 81 89 379 387 B-treatment
EGFR 90 94 388 392 I-treatment
- 94 95 392 393 I-treatment
TKI 95 98 393 396 I-treatment
or 99 101 397 399 O
willing 102 109 400 407 O
to 110 112 408 410 O
consent 113 120 411 418 O
for 121 124 419 422 O
a 125 126 423 424 O
fresh 127 132 425 430 B-treatment
tumor 133 138 431 436 I-treatment
biopsy 139 145 437 443 I-treatment

Any 0 3 444 447 O
clinically 4 14 448 458 O
important 15 24 459 468 O
abnormalities 25 38 469 482 O
in 39 41 483 485 O
rhythm 42 48 486 492 O
, 48 49 492 493 O
conduction 50 60 494 504 O
or 61 63 505 507 O
morphology 64 74 508 518 O
of 75 77 519 521 O
resting 78 85 522 529 O
electrocardiography 86 105 530 549 O
( 106 107 550 551 O
ECG 107 110 551 554 O
) 110 111 554 555 O
( 112 113 556 557 O
e.g. 113 117 557 561 O
, 117 118 561 562 O
complete 119 127 563 571 O
left 128 132 572 576 B-chronic_disease
bundle 133 139 577 583 I-chronic_disease
branch 140 146 584 590 I-chronic_disease
block 147 152 591 596 I-chronic_disease
, 152 153 596 597 O
third 154 159 598 603 B-chronic_disease
degree 160 166 604 610 I-chronic_disease
heart 167 172 611 616 I-chronic_disease
block 173 178 617 622 I-chronic_disease
, 178 179 622 623 O
second 180 186 624 630 B-chronic_disease
degree 187 193 631 637 I-chronic_disease
heart 194 199 638 643 I-chronic_disease
block 200 205 644 649 I-chronic_disease
) 205 206 649 650 O

Any 0 3 651 654 O
factors 4 11 655 662 O
that 12 16 663 667 O
increase 17 25 668 676 O
the 26 29 677 680 O
risk 30 34 681 685 O
of 35 37 686 688 O
QTc 38 41 689 692 B-clinical_variable
prolongation 42 54 693 705 I-clinical_variable
or 55 57 706 708 O
risk 58 62 709 713 O
of 63 65 714 716 O
arrhythmic 66 76 717 727 O
events 77 83 728 734 O
such 84 88 735 739 O
as 89 91 740 742 O
heart 92 97 743 748 B-chronic_disease
failure 98 105 749 756 I-chronic_disease
, 105 106 756 757 O
hypokalemia 107 118 758 769 O
, 118 119 769 770 O
congenital 120 130 771 781 B-chronic_disease
long 131 135 782 786 I-chronic_disease
QT 136 138 787 789 I-chronic_disease
syndrome 139 147 790 798 I-chronic_disease
, 147 148 798 799 O
family 149 155 800 806 O
history 156 163 807 814 O
of 164 166 815 817 O
long 167 171 818 822 O
QT 172 174 823 825 O
syndrome 175 183 826 834 O
or 184 186 835 837 O
unexplained 187 198 838 849 O
sudden 199 205 850 856 O
death 206 211 857 862 O
under 212 217 863 868 O
40 218 220 869 871 B-upper_bound
years 221 226 872 877 I-upper_bound
of 227 229 878 880 O
age 230 233 881 884 B-age
in 234 236 885 887 O
first 237 242 888 893 O
degree 243 249 894 900 O
relatives 250 259 901 910 O
or 260 262 911 913 O
any 263 266 914 917 O
concomitant 267 278 918 929 B-treatment
medication 279 289 930 940 I-treatment
known 290 295 941 946 O
to 296 298 947 949 O
prolong 299 306 950 957 O
the 307 310 958 961 O
QT 311 313 962 964 O
interval 314 322 965 973 O
and 323 326 974 977 O
cause 327 332 978 983 O
torsades 333 341 984 992 B-chronic_disease
de 342 344 993 995 I-chronic_disease
pointes 345 352 996 1003 I-chronic_disease

Any 0 3 1004 1007 O
number 4 10 1008 1014 O
of 11 13 1015 1017 O
prior 14 19 1018 1023 B-treatment
therapies 20 29 1024 1033 I-treatment
is 30 32 1034 1036 O
allowed 33 40 1037 1044 O

Aspartate 0 9 1045 1054 B-clinical_variable
aminotransferase 10 26 1055 1071 I-clinical_variable
( 27 28 1072 1073 I-clinical_variable
AST 28 31 1073 1076 I-clinical_variable
) 31 32 1076 1077 I-clinical_variable
( 33 34 1078 1079 O
serum 34 39 1079 1084 B-clinical_variable
glutamic 40 48 1085 1093 I-clinical_variable
- 48 49 1093 1094 I-clinical_variable
oxaloacetic 49 60 1094 1105 I-clinical_variable
transaminase 61 73 1106 1118 I-clinical_variable
[ 74 75 1119 1120 I-clinical_variable
SGOT])/alanine 75 89 1120 1134 I-clinical_variable
aminotransferase 90 106 1135 1151 I-clinical_variable
( 107 108 1152 1153 I-clinical_variable
ALT 108 111 1153 1156 I-clinical_variable
) 111 112 1156 1157 I-clinical_variable
( 113 114 1158 1159 I-clinical_variable
serum 114 119 1159 1164 I-clinical_variable
glutamate 120 129 1165 1174 I-clinical_variable
pyruvate 130 138 1175 1183 I-clinical_variable
transaminase 139 151 1184 1196 I-clinical_variable
[ 152 153 1197 1198 I-clinical_variable
SGPT 153 157 1198 1202 I-clinical_variable
] 157 158 1202 1203 I-clinical_variable
) 158 159 1203 1204 O
= 160 161 1205 1206 O
< 161 162 1206 1207 O
3.0 163 166 1208 1211 B-upper_bound
x 167 168 1212 1213 I-upper_bound
institutional 169 182 1214 1227 I-upper_bound
upper 183 188 1228 1233 I-upper_bound
limit 189 194 1234 1239 I-upper_bound
of 195 197 1240 1242 I-upper_bound
normal 198 204 1243 1249 I-upper_bound

Corticosteroids 0 15 1250 1265 B-treatment
prescribed 16 26 1266 1276 O
for 27 30 1277 1280 O
the 31 34 1281 1284 O
management 35 45 1285 1295 O
of 46 48 1296 1298 O
brain 49 54 1299 1304 B-cancer
metastases 55 65 1305 1315 I-cancer
have 66 70 1316 1320 O
been 71 75 1321 1325 O
discontinued 76 88 1326 1338 O
at 89 91 1339 1341 O
least 92 97 1342 1347 O
7 98 99 1348 1349 B-lower_bound
days 100 104 1350 1354 I-lower_bound
prior 105 110 1355 1360 I-lower_bound
to 111 113 1361 1363 O
registration 114 126 1364 1376 O

Creatinine 0 10 1377 1387 B-clinical_variable
= 11 12 1388 1389 O
< 12 13 1389 1390 O
1.5 14 17 1391 1394 B-upper_bound
x 18 19 1395 1396 I-upper_bound
ULN 20 23 1397 1400 I-upper_bound

Creatinine 0 10 1401 1411 B-clinical_variable
clearance 11 20 1412 1421 I-clinical_variable
> 21 22 1422 1423 O
= 22 23 1423 1424 O
50 24 26 1425 1427 B-lower_bound
mL 27 29 1428 1430 I-lower_bound
/ 29 30 1430 1431 I-lower_bound
min 30 33 1431 1434 I-lower_bound

Double 0 6 1435 1441 O
- 6 7 1441 1442 O
barrier 7 14 1442 1449 O
method 15 21 1450 1456 O
: 21 22 1456 1457 O
male 23 27 1458 1462 B-gender
condom 28 34 1463 1469 B-contraception_consent
plus 35 39 1470 1474 I-contraception_consent
diaphragm 40 49 1475 1484 I-contraception_consent
or 50 52 1485 1487 I-contraception_consent
vaginal 53 60 1488 1495 I-contraception_consent
cap 61 64 1496 1499 I-contraception_consent
with 65 69 1500 1504 I-contraception_consent
spermicide 70 80 1505 1515 I-contraception_consent
( 81 82 1516 1517 O
contraceptive 82 95 1517 1530 B-contraception_consent
sponge 96 102 1531 1537 I-contraception_consent
, 102 103 1537 1538 O
jellies 104 111 1539 1546 B-contraception_consent
or 112 114 1547 1549 O
creams 115 121 1550 1556 B-contraception_consent
) 121 122 1556 1557 O

Eastern 0 7 1558 1565 B-clinical_variable
Cooperative 8 19 1566 1577 I-clinical_variable
Oncology 20 28 1578 1586 I-clinical_variable
Group 29 34 1587 1592 I-clinical_variable
( 35 36 1593 1594 I-clinical_variable
ECOG 36 40 1594 1598 I-clinical_variable
) 40 41 1598 1599 I-clinical_variable
performance 42 53 1600 1611 I-clinical_variable
status 54 60 1612 1618 I-clinical_variable
= 61 62 1619 1620 O
< 62 63 1620 1621 O
1 64 65 1622 1623 B-upper_bound

Exon 0 4 1624 1628 O
21 5 7 1629 1631 O
L858R 8 13 1632 1637 O
, 13 14 1637 1638 O
Exon 15 19 1639 1643 O
19 20 22 1644 1646 O
deletion 23 31 1647 1655 O
, 31 32 1655 1656 O
Exon 33 37 1657 1661 O
18 38 40 1662 1664 O
G719X 41 46 1665 1670 O
, 46 47 1670 1671 O
Exon 48 52 1672 1676 O
21 53 55 1677 1679 O
L861Q 56 61 1680 1685 O
or 62 64 1686 1688 O
for 65 68 1689 1692 O
EGFR 69 73 1693 1697 O
Exon 74 78 1698 1702 O
20 79 81 1703 1705 O
insertion 82 91 1706 1715 O
expansion 92 101 1716 1725 O
cohort 102 108 1726 1732 O
D 109 110 1733 1734 O
, 110 111 1734 1735 O
NSCLC 112 117 1736 1741 B-cancer
must 118 122 1742 1746 O
harbor 123 129 1747 1753 O
an 130 132 1754 1756 O
EGFR 133 137 1757 1761 O
Exon 138 142 1762 1766 O
20 143 145 1767 1769 O
insertion 146 155 1770 1779 O
performed 156 165 1780 1789 O
by 166 168 1790 1792 O
a 169 170 1793 1794 O
Clinical 171 179 1795 1803 O
Laboratory 180 190 1804 1814 O
Improvement 191 202 1815 1826 O
Act 203 206 1827 1830 O
( 207 208 1831 1832 O
CLIA 208 212 1832 1836 O
) 212 213 1836 1837 O
certified 214 223 1838 1847 O
test 224 228 1848 1852 O

Human 0 5 1853 1858 B-chronic_disease
immunodeficiency 6 22 1859 1875 I-chronic_disease
virus 23 28 1876 1881 I-chronic_disease
( 29 30 1882 1883 I-chronic_disease
HIV)-positive 30 43 1883 1896 I-chronic_disease
patients 44 52 1897 1905 O
on 53 55 1906 1908 O
combination 56 67 1909 1920 B-treatment
antiretroviral 68 82 1921 1935 I-treatment
therapy 83 90 1936 1943 I-treatment
are 91 94 1944 1947 O
ineligible 95 105 1948 1958 O
because 106 113 1959 1966 O
of 114 116 1967 1969 O
the 117 120 1970 1973 O
potential 121 130 1974 1983 O
for 131 134 1984 1987 O
pharmacokinetic 135 150 1988 2003 O
interactions 151 163 2004 2016 O
with 164 168 2017 2021 O
AZD9291 169 176 2022 2029 B-treatment

Left 0 4 2030 2034 B-clinical_variable
ventricular 5 16 2035 2046 I-clinical_variable
ejection 17 25 2047 2055 I-clinical_variable
fraction 26 34 2056 2064 I-clinical_variable
< 35 36 2065 2066 O
50 37 39 2067 2069 B-upper_bound
% 39 40 2069 2070 I-upper_bound
on 41 43 2071 2073 O
echocardiogram 44 58 2074 2088 B-treatment
or 59 61 2089 2091 O
multi 62 67 2092 2097 B-treatment
- 67 68 2097 2098 I-treatment
gated 68 73 2098 2103 I-treatment
acquisition 74 85 2104 2115 I-treatment
( 86 87 2116 2117 I-treatment
MUGA 87 91 2117 2121 I-treatment
) 91 92 2121 2122 I-treatment

Life 0 4 2123 2127 B-clinical_variable
expectancy 5 15 2128 2138 I-clinical_variable
of 16 18 2139 2141 O
greater 19 26 2142 2149 O
3 27 28 2150 2151 B-lower_bound
months 29 35 2152 2158 I-lower_bound

Major 0 5 2159 2164 B-treatment
surgery 6 13 2165 2172 I-treatment
within 14 20 2173 2179 O
21 21 23 2180 2182 B-upper_bound
days 24 28 2183 2187 I-upper_bound
of 29 31 2188 2190 O
starting 32 40 2191 2199 O
protocol 41 49 2200 2208 O
treatment 50 59 2209 2218 B-treatment

Mean 0 4 2219 2223 B-clinical_variable
resting 5 12 2224 2231 I-clinical_variable
corrected 13 22 2232 2241 I-clinical_variable
QT 23 25 2242 2244 I-clinical_variable
interval 26 34 2245 2253 I-clinical_variable
( 35 36 2254 2255 I-clinical_variable
QTc 36 39 2255 2258 I-clinical_variable
using 40 45 2259 2264 I-clinical_variable
Fridericia 46 56 2265 2275 I-clinical_variable
's 56 58 2275 2277 I-clinical_variable
formula 59 66 2278 2285 I-clinical_variable
[ 67 68 2286 2287 I-clinical_variable
QTcF 68 72 2287 2291 I-clinical_variable
] 72 73 2291 2292 I-clinical_variable
) 73 74 2292 2293 I-clinical_variable
> 75 76 2294 2295 O
470 77 80 2296 2299 B-lower_bound
msec 81 85 2300 2304 I-lower_bound

Past 0 4 2305 2309 O
medical 5 12 2310 2317 O
history 13 20 2318 2325 O
of 21 23 2326 2328 O
interstitial 24 36 2329 2341 B-chronic_disease
lung 37 41 2342 2346 I-chronic_disease
disease 42 49 2347 2354 I-chronic_disease
, 49 50 2354 2355 O
drug 51 55 2356 2360 B-chronic_disease
- 55 56 2360 2361 I-chronic_disease
induced 56 63 2361 2368 I-chronic_disease
interstitial 64 76 2369 2381 I-chronic_disease
lung 77 81 2382 2386 I-chronic_disease
disease 82 89 2387 2394 I-chronic_disease
, 89 90 2394 2395 O
radiation 91 100 2396 2405 B-chronic_disease
pneumonitis 101 112 2406 2417 I-chronic_disease
requiring 113 122 2418 2427 O
steroid 123 130 2428 2435 B-treatment
treatment 131 140 2436 2445 I-treatment
, 140 141 2445 2446 O
or 142 144 2447 2449 O
any 145 148 2450 2453 O
evidence 149 157 2454 2462 O
of 158 160 2463 2465 O
clinically 161 171 2466 2476 O
active 172 178 2477 2483 O
interstitial 179 191 2484 2496 O
lung 192 196 2497 2501 O
disease 197 204 2502 2509 O

Patients 0 8 2510 2518 O
currently 9 18 2519 2528 O
receiving 19 28 2529 2538 O
( 29 30 2539 2540 O
or 30 32 2540 2542 O
unable 33 39 2543 2549 O
to 40 42 2550 2552 O
stop 43 47 2553 2557 O
use 48 51 2558 2561 O
prior 52 57 2562 2567 O
to 58 60 2568 2570 O
receiving 61 70 2571 2580 O
the 71 74 2581 2584 O
first 75 80 2585 2590 O
dose 81 85 2591 2595 O
of 86 88 2596 2598 O
study 89 94 2599 2604 O
treatment 95 104 2605 2614 B-treatment
) 104 105 2614 2615 O
medications 106 117 2616 2627 B-treatment
or 118 120 2628 2630 O
herbal 121 127 2631 2637 B-treatment
supplements 128 139 2638 2649 I-treatment
known 140 145 2650 2655 O
to 146 148 2656 2658 O
be 149 151 2659 2661 O
potent 152 158 2662 2668 O
inducers 159 167 2669 2677 O
of 168 170 2678 2680 O
CYP3A4 171 177 2681 2687 B-treatment
( 178 179 2688 2689 O
at 179 181 2689 2691 O
least 182 187 2692 2697 O
3 188 189 2698 2699 B-lower_bound
weeks 190 195 2700 2705 I-lower_bound
prior 196 201 2706 2711 I-lower_bound
) 201 202 2711 2712 O

Patients 0 8 2713 2721 O
must 9 13 2722 2726 O
discontinue 14 25 2727 2738 O
previous 26 34 2739 2747 B-treatment
EGFR 35 39 2748 2752 I-treatment
- 39 40 2752 2753 I-treatment
TKI 40 43 2753 2756 I-treatment
at 44 46 2757 2759 O
least 47 52 2760 2765 O
7 53 54 2766 2767 B-lower_bound
days 55 59 2768 2772 I-lower_bound
prior 60 65 2773 2778 I-lower_bound
to 66 68 2779 2781 O
study 69 74 2782 2787 O
enrollment 75 85 2788 2798 O
with 86 90 2799 2803 O
the 91 94 2804 2807 O
exception 95 104 2808 2817 O
that 105 109 2818 2822 O
patients 110 118 2823 2831 O
on 119 121 2832 2834 O
AZD9291 122 129 2835 2842 B-treatment
for 130 133 2843 2846 O
cohorts 134 141 2847 2854 O
B 142 143 2855 2856 O
, 143 144 2856 2857 O
C 145 146 2858 2859 O
and 147 150 2860 2863 O
E 151 152 2864 2865 O
can 153 156 2866 2869 O
continue 157 165 2870 2878 O
AZD9291 166 173 2879 2886 O
and 174 177 2887 2890 O
need 178 182 2891 2895 O
not 183 186 2896 2899 O
discontinue 187 198 2900 2911 O
prior 199 204 2912 2917 O
to 205 207 2918 2920 O
enrollment 208 218 2921 2931 O

Patients 0 8 2932 2940 O
must 9 13 2941 2945 O
have 14 18 2946 2950 O
completed 19 28 2951 2960 O
last 29 33 2961 2965 O
chemotherapy 34 46 2966 2978 B-treatment
> 47 48 2979 2980 O
= 48 49 2980 2981 O
3 50 51 2982 2983 B-lower_bound
weeks 52 57 2984 2989 I-lower_bound
or 58 60 2990 2992 O
radiotherapy 61 73 2993 3005 B-treatment
> 74 75 3006 3007 O
= 75 76 3007 3008 O
2 77 78 3009 3010 B-lower_bound
weeks 79 84 3011 3016 I-lower_bound
prior 85 90 3017 3022 I-lower_bound
to 91 93 3023 3025 O
receiving 94 103 3026 3035 O
study 104 109 3036 3041 B-treatment
drugs 110 115 3042 3047 I-treatment

Patients 0 8 3048 3056 O
must 9 13 3057 3061 O
have 14 18 3062 3066 O
measurable 19 29 3067 3077 O
disease 30 37 3078 3085 O
by 38 40 3086 3088 O
Response 41 49 3089 3097 O
Evaluation 50 60 3098 3108 O
Criteria 61 69 3109 3117 O
in 70 72 3118 3120 O
Solid 73 78 3121 3126 O
Tumors 79 85 3127 3133 O
( 86 87 3134 3135 O
RECIST 87 93 3135 3141 O
) 93 94 3141 3142 O
1.1 95 98 3143 3146 O
, 98 99 3146 3147 O
defined 100 107 3148 3155 O
as 108 110 3156 3158 O
at 111 113 3159 3161 O
least 114 119 3162 3167 O
one 120 123 3168 3171 B-lower_bound
lesion 124 130 3172 3178 O
that 131 135 3179 3183 O
can 136 139 3184 3187 O
be 140 142 3188 3190 O
accurately 143 153 3191 3201 O
measured 154 162 3202 3210 O
in 163 165 3211 3213 O
at 166 168 3214 3216 O
least 169 174 3217 3222 O
one 175 178 3223 3226 O
dimension 179 188 3227 3236 O
> 189 190 3237 3238 O
= 190 191 3238 3239 O
10 192 194 3240 3242 B-lower_bound
mm 195 197 3243 3245 I-lower_bound
( 198 199 3246 3247 O
> 199 200 3247 3248 O
= 200 201 3248 3249 O
1 202 203 3250 3251 B-lower_bound
cm 204 206 3252 3254 I-lower_bound
) 206 207 3254 3255 O
by 208 210 3256 3258 O
computed 211 219 3259 3267 B-treatment
tomography 220 230 3268 3278 I-treatment
( 231 232 3279 3280 I-treatment
CT 232 234 3280 3282 I-treatment
) 234 235 3282 3283 I-treatment
imaging 236 243 3284 3291 I-treatment
or 244 246 3292 3294 O
magnetic 247 255 3295 3303 B-treatment
resonance 256 265 3304 3313 I-treatment
imaging 266 273 3314 3321 I-treatment
( 274 275 3322 3323 I-treatment
MRI 275 278 3323 3326 I-treatment
) 278 279 3326 3327 I-treatment
within 280 286 3328 3334 O
42 287 289 3335 3337 B-upper_bound
days 290 294 3338 3342 I-upper_bound
prior 295 300 3343 3348 I-upper_bound
to 301 303 3349 3351 O
registration 304 316 3352 3364 O

Patients 0 8 3365 3373 O
must 9 13 3374 3378 O
have 14 18 3379 3383 O
recovered 19 28 3384 3393 O
from 29 33 3394 3398 O
adverse 34 41 3399 3406 O
events 42 48 3407 3413 O
attributable 49 61 3414 3426 O
to 62 64 3427 3429 O
previous 65 73 3430 3438 B-treatment
treatment 74 83 3439 3448 I-treatment
to 84 86 3449 3451 O
= 87 88 3452 3453 O
< 88 89 3453 3454 O
grade 90 95 3455 3460 B-upper_bound
1 96 97 3461 3462 I-upper_bound

Patients 0 8 3463 3471 O
who 9 12 3472 3475 O
are 13 16 3476 3479 O
receiving 17 26 3480 3489 O
any 27 30 3490 3493 O
other 31 36 3494 3499 O
investigational 37 52 3500 3515 B-treatment
agents 53 59 3516 3522 I-treatment

Patients 0 8 3523 3531 O
with 9 13 3532 3536 O
active 14 20 3537 3543 O
malignancies 21 33 3544 3556 B-cancer
other 34 39 3557 3562 O
than 40 44 3563 3567 O
NSCLC 45 50 3568 3573 B-cancer
or 51 53 3574 3576 O
prior 54 59 3577 3582 O
curatively 60 70 3583 3593 O
treated 71 78 3594 3601 O
malignancy 79 89 3602 3612 B-cancer
at 90 92 3613 3615 O
high 93 97 3616 3620 O
risk 98 102 3621 3625 O
of 103 105 3626 3628 O
relapse 106 113 3629 3636 O
during 114 120 3637 3643 O
the 121 124 3644 3647 O
study 125 130 3648 3653 O
period 131 137 3654 3660 O
with 138 142 3661 3665 O
the 143 146 3666 3669 O
exception 147 156 3670 3679 O
of 157 159 3680 3682 O
localized 160 169 3683 3692 O
squamous 170 178 3693 3701 B-cancer
or 179 181 3702 3704 O
basal 182 187 3705 3710 B-cancer
cell 188 192 3711 3715 I-cancer
skin 193 197 3716 3720 I-cancer
cancers 198 205 3721 3728 I-cancer

Patients 0 8 3729 3737 O
with 9 13 3738 3742 O
stage 14 19 3743 3748 O
IV 20 22 3749 3751 O
or 23 25 3752 3754 O
recurrent 26 35 3755 3764 O
/ 35 36 3764 3765 O
metastatic 36 46 3765 3775 B-cancer
histologically 47 61 3776 3790 O
confirmed 62 71 3791 3800 O
non 72 75 3801 3804 B-cancer
- 75 76 3804 3805 I-cancer
small 76 81 3805 3810 I-cancer
cell 82 86 3811 3815 I-cancer
lung 87 91 3816 3820 I-cancer
cancer 92 98 3821 3827 I-cancer
( 99 100 3828 3829 I-cancer
NSCLC 100 105 3829 3834 I-cancer
) 105 106 3834 3835 I-cancer

Patients 0 8 3836 3844 O
with 9 13 3845 3849 O
untreated 14 23 3850 3859 O
brain 24 29 3860 3865 B-cancer
metastases 30 40 3866 3876 I-cancer
are 41 44 3877 3880 O
allowed 45 52 3881 3888 O
provided 53 61 3889 3897 O
that 62 66 3898 3902 O
the 67 70 3903 3906 O
patient 71 78 3907 3914 O
is 79 81 3915 3917 O
clinically 82 92 3918 3928 O
asymptomatic 93 105 3929 3941 O
and 106 109 3942 3945 O
stable 110 116 3946 3952 O

Platelets 0 9 3953 3962 B-clinical_variable
> 10 11 3963 3964 O
= 11 12 3964 3965 O
100,000 13 20 3966 3973 B-lower_bound
/ 20 21 3973 3974 I-lower_bound
mcL 21 24 3974 3977 I-lower_bound

The 0 3 3978 3981 O
brain 4 9 3982 3987 B-cancer
metastases 10 20 3988 3998 I-cancer
are 21 24 3999 4002 O
stable 25 31 4003 4009 O
on 32 34 4010 4012 O
pre 35 38 4013 4016 O
- 38 39 4016 4017 O
registration 39 51 4017 4029 O
imaging 52 59 4030 4037 O

The 0 3 4038 4041 O
brain 4 9 4042 4047 B-cancer
metastases 10 20 4048 4058 I-cancer
have 21 25 4059 4063 O
been 26 30 4064 4068 O
treated 31 38 4069 4076 O

The 0 3 4077 4080 O
effects 4 11 4081 4088 O
of 12 14 4089 4091 O
AZD9291 15 22 4092 4099 B-treatment
and 23 26 4100 4103 O
necitumumab 27 38 4104 4115 B-treatment
on 39 41 4116 4118 O
the 42 45 4119 4122 O
developing 46 56 4123 4133 O
human 57 62 4134 4139 O
fetus 63 68 4140 4145 O
are 69 72 4146 4149 O
unknown 73 80 4150 4157 O

The 0 3 4158 4161 O
effects 4 11 4162 4169 O
of 12 14 4170 4172 O
AZD9291 15 22 4173 4180 B-treatment
and 23 26 4181 4184 O
necitumumab 27 38 4185 4196 B-treatment
on 39 41 4197 4199 O
the 42 45 4200 4203 O
developing 46 56 4204 4214 O
human 57 62 4215 4220 O
fetus 63 68 4221 4226 O
are 69 72 4227 4230 O
unknown 73 80 4231 4238 O
; 80 81 4238 4239 O
for 82 85 4240 4243 O
this 86 90 4244 4248 O
reason 91 97 4249 4255 O
and 98 101 4256 4259 O
because 102 109 4260 4267 O
EGFR 110 114 4268 4272 B-treatment
inhibitors 115 125 4273 4283 I-treatment
are 126 129 4284 4287 O
known 130 135 4288 4293 O
to 136 138 4294 4296 O
be 139 141 4297 4299 O
teratogenic 142 153 4300 4311 O
, 153 154 4311 4312 O
pregnant 155 163 4313 4321 B-pregnancy
women 164 169 4322 4327 B-gender
are 170 173 4328 4331 O
excluded 174 182 4332 4340 O
from 183 187 4341 4345 O
this 188 192 4346 4350 O
study 193 198 4351 4356 O
; 198 199 4356 4357 O
because 200 207 4358 4365 O
there 208 213 4366 4371 O
is 214 216 4372 4374 O
an 217 219 4375 4377 O
unknown 220 227 4378 4385 O
but 228 231 4386 4389 O
potential 232 241 4390 4399 O
risk 242 246 4400 4404 O
for 247 250 4405 4408 O
adverse 251 258 4409 4416 O
events 259 265 4417 4423 O
in 266 268 4424 4426 O
nursing 269 276 4427 4434 O
infants 277 284 4435 4442 O
secondary 285 294 4443 4452 O
to 295 297 4453 4455 O
treatment 298 307 4456 4465 B-treatment
of 308 310 4466 4468 O
the 311 314 4469 4472 O
mother 315 321 4473 4479 O
AZD9291 322 329 4480 4487 O
and 330 333 4488 4491 O
necitumumab 334 345 4492 4503 O
breastfeeding 346 359 4504 4517 O
should 360 366 4518 4524 O
be 367 369 4525 4527 O
discontinued 370 382 4528 4540 O
if 383 385 4541 4543 O
the 386 389 4544 4547 O
mother 390 396 4548 4554 O
is 397 399 4555 4557 O
treated 400 407 4558 4565 O
with 408 412 4566 4570 O
AZD9291 413 420 4571 4578 O
and 421 424 4579 4582 O
necitumumab 425 436 4583 4594 O
; 436 437 4594 4595 O
these 438 443 4596 4601 O
potential 444 453 4602 4611 O
risks 454 459 4612 4617 O
may 460 463 4618 4621 O
also 464 468 4622 4626 O
apply 469 474 4627 4632 O
to 475 477 4633 4635 O
other 478 483 4636 4641 O
agents 484 490 4642 4648 O
used 491 495 4649 4653 O
in 496 498 4654 4656 O
this 499 503 4657 4661 O
study 504 509 4662 4667 O

The 0 3 4668 4671 O
patient 4 11 4672 4679 O
is 12 14 4680 4682 O
asymptomatic 15 27 4683 4695 O
from 28 32 4696 4700 O
the 33 36 4701 4704 O
brain 37 42 4705 4710 B-cancer
metastases 43 53 4711 4721 I-cancer
at 54 56 4722 4724 O
enrollment 57 67 4725 4735 O

Total 0 5 4736 4741 O
abstinence 6 16 4742 4752 O
from 17 21 4753 4757 O
sexual 22 28 4758 4764 O
intercourse 29 40 4765 4776 O
( 41 42 4777 4778 O
minimum 42 49 4778 4785 O
one 50 53 4786 4789 B-lower_bound
complete 54 62 4790 4798 O
menstrual 63 72 4799 4808 O
cycle 73 78 4809 4814 O
prior 79 84 4815 4820 B-treatment
to 85 87 4821 4823 I-treatment
study 88 93 4824 4829 I-treatment
drug 94 98 4830 4834 I-treatment
administration 99 113 4835 4849 O
) 113 114 4849 4850 O

Total 0 5 4851 4856 B-clinical_variable
bilirubin 6 15 4857 4866 I-clinical_variable
= 16 17 4867 4868 O
< 17 18 4868 4869 O
1.5 19 22 4870 4873 B-upper_bound
x 23 24 4874 4875 I-upper_bound
upper 25 30 4876 4881 I-upper_bound
limit 31 36 4882 4887 I-upper_bound
of 37 39 4888 4890 I-upper_bound
normal 40 46 4891 4897 I-upper_bound
( 47 48 4898 4899 I-upper_bound
ULN 48 51 4899 4902 I-upper_bound
) 51 52 4902 4903 I-upper_bound
( 53 54 4904 4905 O
patients 54 62 4905 4913 O
with 63 67 4914 4918 O
Gilbert 68 75 4919 4926 B-chronic_disease
's 75 77 4926 4928 I-chronic_disease
syndrome 78 86 4929 4937 I-chronic_disease
may 87 90 4938 4941 O
have 91 95 4942 4946 O
serum 96 101 4947 4952 B-clinical_variable
bilirubin 102 111 4953 4962 I-clinical_variable
> 112 113 4963 4964 O
1.5 114 117 4965 4968 B-lower_bound
ULN 118 121 4969 4972 I-lower_bound
) 121 122 4972 4973 O

Uncontrolled 0 12 4974 4986 O
intercurrent 13 25 4987 4999 O
illness 26 33 5000 5007 O
including 34 43 5008 5017 O
, 43 44 5017 5018 O
but 45 48 5019 5022 O
not 49 52 5023 5026 O
limited 53 60 5027 5034 O
to 61 63 5035 5037 O
, 63 64 5037 5038 O
ongoing 65 72 5039 5046 O
or 73 75 5047 5049 O
active 76 82 5050 5056 B-chronic_disease
infection 83 92 5057 5066 I-chronic_disease
, 92 93 5066 5067 O
symptomatic 94 105 5068 5079 O
congestive 106 116 5080 5090 B-chronic_disease
heart 117 122 5091 5096 I-chronic_disease
failure 123 130 5097 5104 I-chronic_disease
, 130 131 5104 5105 O
unstable 132 140 5106 5114 B-chronic_disease
angina 141 147 5115 5121 I-chronic_disease
pectoris 148 156 5122 5130 O
, 156 157 5130 5131 O
cardiac 158 165 5132 5139 B-chronic_disease
arrhythmia 166 176 5140 5150 I-chronic_disease
, 176 177 5150 5151 O
gastrointestinal 178 194 5152 5168 B-chronic_disease
disease 195 202 5169 5176 I-chronic_disease
limiting 203 211 5177 5185 O
absorption 212 222 5186 5196 O
of 223 225 5197 5199 O
AZD9291 226 233 5200 5207 B-treatment
such 234 238 5208 5212 O
as 239 241 5213 5215 O
a 242 243 5216 5217 O
malabsorption 244 257 5218 5231 B-chronic_disease
syndrome 258 266 5232 5240 I-chronic_disease
or 267 269 5241 5243 O
inflammatory 270 282 5244 5256 B-chronic_disease
bowel 283 288 5257 5262 I-chronic_disease
disease 289 296 5263 5270 I-chronic_disease
or 297 299 5271 5273 O
psychiatric 300 311 5274 5285 B-chronic_disease
illness 312 319 5286 5293 I-chronic_disease
/ 319 320 5293 5294 O
social 320 326 5294 5300 O
situations 327 337 5301 5311 O
that 338 342 5312 5316 O
would 343 348 5317 5322 O
limit 349 354 5323 5328 O
compliance 355 365 5329 5339 O
with 366 370 5340 5344 O
study 371 376 5345 5350 O
requirements 377 389 5351 5363 O

Vasectomized 0 12 5364 5376 O
male 13 17 5377 5381 B-gender
subject 18 25 5382 5389 I-gender
or 26 28 5390 5392 O
vasectomized 29 41 5393 5405 O
partner 42 49 5406 5413 O
of 50 52 5414 5416 O
female 53 59 5417 5423 B-gender
subjects 60 68 5424 5432 I-gender

Women 0 5 5433 5438 B-gender
of 6 8 5439 5441 O
childbearing 9 21 5442 5454 O
potential 22 31 5455 5464 O
must 32 36 5465 5469 O
have 37 41 5470 5474 O
a 42 43 5475 5476 O
negative 44 52 5477 5485 B-pregnancy
urine 53 58 5486 5491 I-pregnancy
pregnancy 59 68 5492 5501 I-pregnancy
test 69 73 5502 5506 O
within 74 80 5507 5513 O
7 81 82 5514 5515 B-upper_bound
days 83 87 5516 5520 I-upper_bound
prior 88 93 5521 5526 I-upper_bound
to 94 96 5527 5529 O
initiation 97 107 5530 5540 O
of 108 110 5541 5543 O
treatment 111 120 5544 5553 B-treatment

all 0 3 5554 5557 O
patients 4 12 5558 5566 O
must 13 17 5567 5571 O
try 18 21 5572 5575 O
to 22 24 5576 5578 O
avoid 25 30 5579 5584 O
concomitant 31 42 5585 5596 O
use 43 46 5597 5600 O
of 47 49 5601 5603 O
any 50 53 5604 5607 O
medications 54 65 5608 5619 B-treatment
, 65 66 5619 5620 O
herbal 67 73 5621 5627 B-treatment
supplements 74 85 5628 5639 I-treatment
and/or 86 92 5640 5646 O
ingestion 93 102 5647 5656 O
of 103 105 5657 5659 O
foods 106 111 5660 5665 O
with 112 116 5666 5670 O
known 117 122 5671 5676 O
inducer 123 130 5677 5684 O
effects 131 138 5685 5692 O
of 139 141 5693 5695 O
CYP3A4 142 148 5696 5702 B-treatment

be 0 2 5703 5705 O
treatment 3 12 5706 5715 O
naive 13 18 5716 5721 O
to 19 21 5722 5724 O
3rd 22 25 5725 5728 O
generation 26 36 5729 5739 O
EGFR 37 41 5740 5744 B-treatment
- 41 42 5744 5745 I-treatment
TKI 42 45 5745 5748 I-treatment
( 46 47 5749 5750 O
rociletinib 47 58 5750 5761 B-treatment
, 58 59 5761 5762 O
EGFR 60 64 5763 5767 B-treatment
inhibitor 65 74 5768 5777 I-treatment
HM61713 75 82 5778 5785 I-treatment
[ 83 84 5786 5787 I-treatment
HM61713 84 91 5787 5794 I-treatment
] 91 92 5794 5795 I-treatment
and 93 96 5796 5799 O
AZD9291 97 104 5800 5807 O
) 104 105 5807 5808 O
and 106 109 5809 5812 O
EGFR 110 114 5813 5817 B-treatment
monoclonal 115 125 5818 5828 I-treatment
antibodies 126 136 5829 5839 I-treatment

be 0 2 5840 5842 O
treatment 3 12 5843 5852 B-treatment
naive 13 18 5853 5858 O
to 19 21 5859 5861 O
an 22 24 5862 5864 O
EGFR 25 29 5865 5869 B-treatment
monoclonal 30 40 5870 5880 I-treatment
antibody 41 49 5881 5889 I-treatment

be 0 2 5890 5892 O
treatment 3 12 5893 5902 B-treatment
na√Øve 13 18 5903 5908 O
to 19 21 5909 5911 O
3rd 22 25 5912 5915 O
generation 26 36 5916 5926 O
and 37 40 5927 5930 O
beyond 41 47 5931 5937 O
EGFR 48 52 5938 5942 B-treatment
- 52 53 5942 5943 I-treatment
TKI 53 56 5943 5946 I-treatment
( 57 58 5947 5948 O
i.e. 58 62 5948 5952 O
, 62 63 5952 5953 O
osimertinib 64 75 5954 5965 B-treatment
, 75 76 5965 5966 O
poziotinib 77 87 5967 5977 B-treatment
, 87 88 5977 5978 O
TAK-778 89 96 5979 5986 B-treatment
) 96 97 5986 5987 O
and 98 101 5988 5991 O
EGFR 102 106 5992 5996 O
monoclonal 107 117 5997 6007 O
antibody 118 126 6008 6016 O
; 126 127 6016 6017 O
patient 128 135 6018 6025 O
who 136 139 6026 6029 O
received 140 148 6030 6038 O
1st 149 152 6039 6042 O
or 153 155 6043 6045 O
2nd 156 159 6046 6049 O
generation 160 170 6050 6060 O
EGFR 171 175 6061 6065 O
- 175 176 6065 6066 O
TKI 176 179 6066 6069 O
( 180 181 6070 6071 O
such 181 185 6071 6075 O
as 186 188 6076 6078 O
erlotinib 189 198 6079 6088 B-treatment
, 198 199 6088 6089 O
gefitinib 200 209 6090 6099 B-treatment
, 209 210 6099 6100 O
afatinib 211 219 6101 6109 B-treatment
) 219 220 6109 6110 O
are 221 224 6111 6114 O
eligible 225 233 6115 6123 O
provided 234 242 6124 6132 O
that 243 247 6133 6137 O
they 248 252 6138 6142 O
did 253 256 6143 6146 O
not 257 260 6147 6150 O
achieve 261 268 6151 6158 O
a 269 270 6159 6160 O
response 271 279 6161 6169 O
to 280 282 6170 6172 O
treatment 283 292 6173 6182 O
or 293 295 6183 6185 O
they 296 300 6186 6190 O
did 301 304 6191 6194 O
not 305 308 6195 6198 O
have 309 313 6199 6203 O
a 314 315 6204 6205 O
duration 316 324 6206 6214 O
of 325 327 6215 6217 O
treatment 328 337 6218 6227 O
on 338 340 6228 6230 O
EGFR 341 345 6231 6235 O
- 345 346 6235 6236 O
TKI 346 349 6236 6239 O
of 350 352 6240 6242 O
6 353 354 6243 6244 B-lower_bound
months 355 361 6245 6251 I-lower_bound
or 362 364 6252 6254 O
more 365 369 6255 6259 O

for 0 3 6260 6263 O
alopecia 4 12 6264 6272 B-clinical_variable
and 13 16 6273 6276 O
sensory 17 24 6277 6284 B-clinical_variable
neuropathy 25 35 6285 6295 I-clinical_variable
= 36 37 6296 6297 O
< 37 38 6297 6298 O
grade 39 44 6299 6304 B-upper_bound
2 45 46 6305 6306 I-upper_bound

have 0 4 6307 6311 O
a 5 6 6312 6313 O
biopsy 7 13 6314 6320 B-treatment
of 14 16 6321 6323 O
tumor 17 22 6324 6329 B-cancer
taken 23 28 6330 6335 O
after 29 34 6336 6341 O
progression 35 46 6342 6353 O
on 47 49 6354 6356 O
last 50 54 6357 6361 O
EGFR 55 59 6362 6366 B-chronic_disease
- 59 60 6366 6367 I-chronic_disease
TKI 60 63 6367 6370 I-chronic_disease
that 64 68 6371 6375 O
indicates 69 78 6376 6385 O
loss 79 83 6386 6390 O
of 84 86 6391 6393 O
EGFR 87 91 6394 6398 B-chronic_disease
- 91 92 6398 6399 I-chronic_disease
T790 92 96 6399 6403 I-chronic_disease
M 96 97 6403 6404 I-chronic_disease
( 98 99 6405 6406 O
EGFR 99 103 6406 6410 O
- 103 104 6410 6411 O
T790 104 108 6411 6415 O
M 108 109 6415 6416 O
negative 110 118 6417 6425 O
) 118 119 6425 6426 O
confirmed 120 129 6427 6436 O
by 130 132 6437 6439 O
central 133 140 6440 6447 O
testing 141 148 6448 6455 O
prior 149 154 6456 6461 O
to 155 157 6462 6464 O
treatment 158 167 6465 6474 B-treatment
( 168 169 6475 6476 O
if 169 171 6476 6478 O
EGFR 172 176 6479 6483 O
- 176 177 6483 6484 O
T790 177 181 6484 6488 O
M 181 182 6488 6489 O
status 183 189 6490 6496 O
is 190 192 6497 6499 O
unknown 193 200 6500 6507 O
, 200 201 6507 6508 O
patients 202 210 6509 6517 O
may 211 214 6518 6521 O
consent 215 222 6522 6529 O
for 223 226 6530 6533 O
trial 227 232 6534 6539 O
and 233 236 6540 6543 O
for 237 240 6544 6547 O
biopsy 241 247 6548 6554 O
, 247 248 6554 6555 O
and 249 252 6556 6559 O
testing 253 260 6560 6567 O
for 261 264 6568 6571 O
EGFR 265 269 6572 6576 B-chronic_disease
T790 270 274 6577 6581 I-chronic_disease
M 274 275 6581 6582 I-chronic_disease
will 276 280 6583 6587 O
be 281 283 6588 6590 O
performed 284 293 6591 6600 O
as 294 296 6601 6603 O
part 297 301 6604 6608 O
of 302 304 6609 6611 O
initial 305 312 6612 6619 O
biopsy 313 319 6620 6626 O
for 320 323 6627 6630 O
trial 324 329 6631 6636 O
) 329 330 6636 6637 O

have 0 4 6638 6642 O
a 5 6 6643 6644 O
biopsy 7 13 6645 6651 B-treatment
of 14 16 6652 6654 O
tumor 17 22 6655 6660 B-cancer
taken 23 28 6661 6666 O
after 29 34 6667 6672 O
progression 35 46 6673 6684 O
on 47 49 6685 6687 O
last 50 54 6688 6692 O
EGFR 55 59 6693 6697 B-treatment
- 59 60 6697 6698 I-treatment
TKI 60 63 6698 6701 I-treatment
that 64 68 6702 6706 O
indicates 69 78 6707 6716 O
preservation 79 91 6717 6729 O
of 92 94 6730 6732 O
EGFR 95 99 6733 6737 B-treatment
- 99 100 6737 6738 I-treatment
T790 100 104 6738 6742 I-treatment
M 104 105 6742 6743 I-treatment
post 106 110 6744 6748 O
- 110 111 6748 6749 O
progression 111 122 6749 6760 O
on 123 125 6761 6763 O
3rd 126 129 6764 6767 O
generation 130 140 6768 6778 O
EGFR 141 145 6779 6783 B-treatment
- 145 146 6783 6784 I-treatment
TKI 146 149 6784 6787 I-treatment
with 150 154 6788 6792 I-treatment
biopsy 155 161 6793 6799 I-treatment
confirmation 162 174 6800 6812 O
by 175 177 6813 6815 O
central 178 185 6816 6823 O
testing 186 193 6824 6831 O
prior 194 199 6832 6837 B-treatment
to 200 202 6838 6840 I-treatment
treatment 203 212 6841 6850 I-treatment
( 213 214 6851 6852 O
if 214 216 6852 6854 O
EGFR 217 221 6855 6859 O
- 221 222 6859 6860 O
T790 222 226 6860 6864 O
M 226 227 6864 6865 O
status 228 234 6866 6872 O
is 235 237 6873 6875 O
unknown 238 245 6876 6883 O
, 245 246 6883 6884 O
patients 247 255 6885 6893 O
may 256 259 6894 6897 O
consent 260 267 6898 6905 O
for 268 271 6906 6909 O
trial 272 277 6910 6915 O
and 278 281 6916 6919 O
for 282 285 6920 6923 O
biopsy 286 292 6924 6930 O
, 292 293 6930 6931 O
and 294 297 6932 6935 O
testing 298 305 6936 6943 O
for 306 309 6944 6947 O
EGFR 310 314 6948 6952 B-treatment
T790 315 319 6953 6957 I-treatment
M 319 320 6957 6958 I-treatment
will 321 325 6959 6963 O
be 326 328 6964 6966 O
performed 329 338 6967 6976 O
as 339 341 6977 6979 O
part 342 346 6980 6984 O
of 347 349 6985 6987 O
initial 350 357 6988 6995 O
biopsy 358 364 6996 7002 O
for 365 368 7003 7006 O
trial 369 374 7007 7012 O
) 374 375 7012 7013 O

have 0 4 7014 7018 O
biopsy 5 11 7019 7025 B-treatment
of 12 14 7026 7028 O
tumor 15 20 7029 7034 B-cancer
taken 21 26 7035 7040 O
after 27 32 7041 7046 O
progression 33 44 7047 7058 O
on 45 47 7059 7061 O
erlotinib 48 57 7062 7071 B-treatment
, 57 58 7071 7072 O
gefitinib 59 68 7073 7082 B-treatment
or 69 71 7083 7085 O
afatinib 72 80 7086 7094 B-treatment
which 81 86 7095 7100 O
must 87 91 7101 7105 O
be 92 94 7106 7108 O
EGFR 95 99 7109 7113 B-clinical_variable
- 99 100 7113 7114 I-clinical_variable
T790 100 104 7114 7118 I-clinical_variable
M 104 105 7118 7119 I-clinical_variable
negative 106 114 7120 7128 O
confirmed 115 124 7129 7138 O
by 125 127 7139 7141 O
central 128 135 7142 7149 O
testing 136 143 7150 7157 O
prior 144 149 7158 7163 O
to 150 152 7164 7166 O
treatment 153 162 7167 7176 B-treatment
( 163 164 7177 7178 O
if 164 166 7178 7180 O
EGFR 167 171 7181 7185 O
- 171 172 7185 7186 O
T790 172 176 7186 7190 O
M 176 177 7190 7191 O
status 178 184 7192 7198 O
is 185 187 7199 7201 O
unknown 188 195 7202 7209 O
, 195 196 7209 7210 O
patients 197 205 7211 7219 O
may 206 209 7220 7223 O
consent 210 217 7224 7231 O
for 218 221 7232 7235 O
trial 222 227 7236 7241 O
and 228 231 7242 7245 O
for 232 235 7246 7249 O
biopsy 236 242 7250 7256 O
and 243 246 7257 7260 O
testing 247 254 7261 7268 O
for 255 258 7269 7272 O
EGFR 259 263 7273 7277 B-clinical_variable
T790 264 268 7278 7282 I-clinical_variable
M 268 269 7282 7283 I-clinical_variable
will 270 274 7284 7288 O
be 275 277 7289 7291 O
performed 278 287 7292 7301 O
as 288 290 7302 7304 O
part 291 295 7305 7309 O
of 296 298 7310 7312 O
initial 299 306 7313 7320 O
biopsy 307 313 7321 7327 O
for 314 317 7328 7331 O
trial 318 323 7332 7337 O
) 323 324 7337 7338 O

have 0 4 7339 7343 O
progression 5 16 7344 7355 O
of 17 19 7356 7358 O
disease 20 27 7359 7366 O
on 28 30 7367 7369 O
a 31 32 7370 7371 O
3rd 33 36 7372 7375 O
generation 37 47 7376 7386 O
EGFR 48 52 7387 7391 O
- 52 53 7391 7392 O
TKI 53 56 7392 7395 O
such 57 61 7396 7400 O
as 62 64 7401 7403 O
AZD9291 65 72 7404 7411 B-treatment
, 72 73 7411 7412 O
rociletinib 74 85 7413 7424 B-treatment
, 85 86 7424 7425 O
HM61713 87 94 7426 7433 B-treatment

have 0 4 7434 7438 O
progression 5 16 7439 7450 O
of 17 19 7451 7453 O
disease 20 27 7454 7461 O
on 28 30 7462 7464 O
erlotinib 31 40 7465 7474 B-treatment
, 40 41 7474 7475 O
gefitinib 42 51 7476 7485 B-treatment
or 52 54 7486 7488 O
afatinib 55 63 7489 7497 B-treatment
as 64 66 7498 7500 O
last 67 71 7501 7505 B-treatment
previous 72 80 7506 7514 I-treatment
systemic 81 89 7515 7523 I-treatment
treatment 90 99 7524 7533 I-treatment

have 0 4 7534 7538 O
progressive 5 16 7539 7550 B-chronic_disease
disease 17 24 7551 7558 I-chronic_disease
on 25 27 7559 7561 O
or 28 30 7562 7564 O
after 31 36 7565 7570 O
platinum 37 45 7571 7579 B-treatment
based 46 51 7580 7585 I-treatment
chemotherapy 52 64 7586 7598 I-treatment

patient 0 7 7599 7606 O
must 8 12 7607 7611 O
have 13 17 7612 7616 O
progressive 18 29 7617 7628 B-chronic_disease
disease 30 37 7629 7636 I-chronic_disease
on 38 40 7637 7639 O
AZD9291 41 48 7640 7647 B-treatment
as 49 51 7648 7650 O
first 52 57 7651 7656 O
- 57 58 7656 7657 O
line 58 62 7657 7661 O
EGFR 63 67 7662 7666 B-treatment
- 67 68 7666 7667 I-treatment
TKI 68 71 7667 7670 I-treatment
treatment 72 81 7671 7680 I-treatment
for 82 85 7681 7684 O
metastatic 86 96 7685 7695 B-cancer
NSCLC 97 102 7696 7701 I-cancer

patients 0 8 7702 7710 O
must 9 13 7711 7715 O
also 14 18 7716 7720 O
be 19 21 7721 7723 O
treatment 22 31 7724 7733 B-treatment
naive 32 37 7734 7739 O
to 38 40 7740 7742 O
EGFR 41 45 7743 7747 O
- 45 46 7747 7748 O
monoclonal 46 56 7748 7758 O
antibody 57 65 7759 7767 O

patients 0 8 7768 7776 O
must 9 13 7777 7781 O
have 14 18 7782 7786 O
discontinued 19 31 7787 7799 O
any 32 35 7800 7803 O
other 36 41 7804 7809 B-treatment
investigational 42 57 7810 7825 I-treatment
agents 58 64 7826 7832 I-treatment
for 65 68 7833 7836 O
at 69 71 7837 7839 O
least 72 77 7840 7845 O
5 78 79 7846 7847 B-lower_bound
half 80 84 7848 7852 I-lower_bound
- 84 85 7852 7853 I-lower_bound
lives 85 90 7853 7858 I-lower_bound
or 91 93 7859 7861 O
3 94 95 7862 7863 B-lower_bound
months 96 102 7864 7870 I-lower_bound
, 102 103 7870 7871 O
whichever 104 113 7872 7881 O
is 114 116 7882 7884 O
greater 117 124 7885 7892 O
, 124 125 7892 7893 O
prior 126 131 7894 7899 O
to 132 134 7900 7902 O
initiation 135 145 7903 7913 O
of 146 148 7914 7916 O
osimertinib 149 160 7917 7928 B-treatment
in 161 163 7929 7931 O
an 164 166 7932 7934 O
investigational 167 182 7935 7950 O
setting 183 190 7951 7958 O

patients 0 8 7959 7967 O
with 9 13 7968 7972 O
a 14 15 7973 7974 O
prior 16 21 7975 7980 O
history 22 29 7981 7988 O
of 30 32 7989 7991 O
symptomatic 33 44 7992 8003 O
brain 45 50 8004 8009 B-cancer
metastases 51 61 8010 8020 I-cancer
are 62 65 8021 8024 O
eligible 66 74 8025 8033 O
provided 75 83 8034 8042 O

should 0 6 8043 8049 O
a 7 8 8050 8051 O
woman 9 14 8052 8057 B-gender
become 15 21 8058 8064 O
pregnant 22 30 8065 8073 B-pregnancy
or 31 33 8074 8076 O
suspect 34 41 8077 8084 O
she 42 45 8085 8088 O
is 46 48 8089 8091 O
pregnant 49 57 8092 8100 O
while 58 63 8101 8106 O
she 64 67 8107 8110 O
or 68 70 8111 8113 O
her 71 74 8114 8117 O
partner 75 82 8118 8125 O
is 83 85 8126 8128 O
participating 86 99 8129 8142 O
in 100 102 8143 8145 O
this 103 107 8146 8150 O
study 108 113 8151 8156 O
, 113 114 8156 8157 O
she 115 118 8158 8161 O
should 119 125 8162 8168 O
inform 126 132 8169 8175 O
her 133 136 8176 8179 O
treating 137 145 8180 8188 O
physician 146 155 8189 8198 O
immediately 156 167 8199 8210 O

tumor 0 5 8211 8216 B-cancer
that 6 10 8217 8221 O
harbors 11 18 8222 8229 O
an 19 21 8230 8232 O
EGFR 22 26 8233 8237 B-cancer
Exon 27 31 8238 8242 I-cancer
20 32 34 8243 8245 I-cancer
insertion 35 44 8246 8255 O
by 45 47 8256 8258 O
a 48 49 8259 8260 O
CLIA 50 54 8261 8265 O
certified 55 64 8266 8275 O
test 65 69 8276 8280 O

women 0 5 8281 8286 B-gender
of 6 8 8287 8289 O
child 9 14 8290 8295 O
- 14 15 8295 8296 O
bearing 15 22 8296 8303 O
potential 23 32 8304 8313 O
and 33 36 8314 8317 O
men 37 40 8318 8321 O
must 41 45 8322 8326 O
agree 46 51 8327 8332 B-contraception_consent
to 52 54 8333 8335 I-contraception_consent
use 55 58 8336 8339 I-contraception_consent
adequate 59 67 8340 8348 I-contraception_consent
contraception 68 81 8349 8362 I-contraception_consent
using 82 87 8363 8368 O
one 88 91 8369 8372 O
of 92 94 8373 8375 O
the 95 98 8376 8379 O
methods 99 106 8380 8387 O
listed 107 113 8388 8394 O
below 114 119 8395 8400 O
prior 120 125 8401 8406 O
to 126 128 8407 8409 O
study 129 134 8410 8415 O
entry 135 140 8416 8421 O
, 140 141 8421 8422 O
for 142 145 8423 8426 O
the 146 149 8427 8430 O
duration 150 158 8431 8439 O
of 159 161 8440 8442 O
study 162 167 8443 8448 O
participation 168 181 8449 8462 O
, 181 182 8462 8463 O
and 183 186 8464 8467 O
for 187 190 8468 8471 O
3 191 192 8472 8473 B-upper_bound
months 193 199 8474 8480 I-upper_bound
for 200 203 8481 8484 O
women 204 209 8485 8490 O
and 210 213 8491 8494 O
6 214 215 8495 8496 B-upper_bound
months 216 222 8497 8503 I-upper_bound
for 223 226 8504 8507 O
men 227 230 8508 8511 O
following 231 240 8512 8521 O
the 241 244 8522 8525 O
date 245 249 8526 8530 O
of 250 252 8531 8533 O
the 253 256 8534 8537 O
last 257 261 8538 8542 O
dose 262 266 8543 8547 O
of 267 269 8548 8550 O
AZD9291 270 277 8551 8558 B-treatment
and/or 278 284 8559 8565 O
necitumumab 285 296 8566 8577 B-treatment

women 0 5 8578 8583 B-gender
will 6 10 8584 8588 O
be 11 13 8589 8591 O
considered 14 24 8592 8602 O
not 25 28 8603 8606 O
of 29 31 8607 8609 O
childbearing 32 44 8610 8622 O
potential 45 54 8623 8632 O
if 55 57 8633 8635 O
they 58 62 8636 8640 O
are 63 66 8641 8644 O
surgically 67 77 8645 8655 O
sterile 78 85 8656 8663 O
( 86 87 8664 8665 O
bilateral 87 96 8665 8674 O
oophorectomy 97 109 8675 8687 O
or 110 112 8688 8690 O
hysterectomy 113 125 8691 8703 O
) 125 126 8703 8704 O
and/or 127 133 8705 8711 O
post 134 138 8712 8716 O
menopausal 139 149 8717 8727 O
( 150 151 8728 8729 O
amenorrheic 151 162 8729 8740 B-chronic_disease
for 163 166 8741 8744 O
at 167 169 8745 8747 O
least 170 175 8748 8753 O
12 176 178 8754 8756 B-lower_bound
months 179 185 8757 8763 I-lower_bound
) 185 186 8763 8764 O

